BICO Group AB (publ), formerly known as CELLINK AB, is a biotechnology company specializing in the development and commercialization of tools and solutions for life science research. The company’s core offerings include advanced 3D bioprinters, proprietary bioinks, microfluidic devices and cell analytics instruments. These technologies are designed to accelerate drug discovery, tissue engineering and personalized medicine by enabling researchers to create and analyze complex biological models in vitro.
In addition to its flagship bioprinting platforms, BICO provides a broad portfolio of consumables and software that support end-to-end workflows for cell culture and bioprocessing. Its bioinks are formulated for compatibility with a wide range of cell types and applications, while its imaging and analytics systems offer high-resolution, real-time monitoring of cellular behavior. The company also offers technical support and training services to help laboratories integrate new technologies into existing research pipelines.
Founded in 2016 through the merger of CELLINK and other life science technology firms, BICO has pursued a strategy of strategic acquisitions to broaden its product range and geographic reach. Since its initial listing on Nasdaq Stockholm in 2017, the company has expanded operations across Europe, North America and Asia, establishing subsidiary offices and distribution partnerships to serve academic institutions, contract research organizations and pharmaceutical companies worldwide.
BICO is led by co-founder and CEO Erik Gatenholm, whose background in bioengineering has guided the company’s rapid growth and innovation. Under Gatenholm’s leadership, BICO continues to invest in research and development, aiming to advance the adoption of biofabrication technologies and support the translation of laboratory discoveries into therapeutic and diagnostic solutions.
AI Generated. May Contain Errors.